Atherosclerosis
Volume 175, Issue 1 , Pages 39-49 , July 2004

The antiatherogenic potential of oat phenolic compounds

  • Liping Liu

      Affiliations

    • Vascular Biology Laboratory, JM USDA Human Nutrition Research Center on Aging at Tufts University, 711 Washington Street, Boston, MA 02111, USA
    • ,
  • Ligia Zubik

      Affiliations

    • Vascular Biology Laboratory, JM USDA Human Nutrition Research Center on Aging at Tufts University, 711 Washington Street, Boston, MA 02111, USA
    • ,
  • F.William Collins

      Affiliations

    • Eastern Cereals and Oilseeds Research Center (ECORC), Agriculture and Agri-Food Canada, Center Experimental Farm, Ottawa, Ont., Canada K1 A 0C6
    • ,
  • Melissa Marko

      Affiliations

    • Vascular Biology Laboratory, JM USDA Human Nutrition Research Center on Aging at Tufts University, 711 Washington Street, Boston, MA 02111, USA
    • ,
  • Mohsen Meydani

      Affiliations

    • Vascular Biology Laboratory, JM USDA Human Nutrition Research Center on Aging at Tufts University, 711 Washington Street, Boston, MA 02111, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-617-556-3126; fax: +1-617-556-3224.

Received 2 May 2003 ,Revised 19 December 2003 ,Accepted 28 January 2004.

References 

  1. Meydani M. Nutrition, immune cells, and atherosclerosis. Nutr. Rev. 1998;56:S177–S182
  2. Stemme S, Hansson GK. Immune mechanisms in atherogenesis. Ann. Med. 1994;26:141–146
  3. Dustin ML, Rothlein R, Bhan AK, Dinarello CA, Springer TA. Induction by IL-1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J. Immunol. 1986;137:245–254
  4. Collins T. Endothelial nuclear factor-kappa B and the initiation of the atherosclerotic lesion. Lab. Invest. 1993;68:499–508
  5. Strieter RM, Koch AE, Antony VB, et al.  The immunopathology of chemotactic cytokines: the role of interleukin-8 and monocyte chemoattractantprotein-1. J. Lab. Clin. Med. 1994;123:183–197
  6. Cybulsky MI, Gimbrone MA. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science. 1991;251:788–791
  7. Li H, Cybulsky MI, Gimbrone MA, Libby P. An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. Arterioscler. Thromb. 1993;13:197–204
  8. Reape TJ, Groot PH. Chemokines and atherosclerosis. Atherosclerosis. 1999;147:213–225
  9. Xu L, Kelvin DJ, Ye GQ, et al.  Modulation of IL-8 receptor expression on purified human T lymphocytes is associated with changed chemotactic responses to IL-8a. J. Leuk. Biol. 1995;57:335–342
  10. Yue TL, Wang X, Sung CP, et al.  Interleukin-8: a mitogen and chemoattractant for vascular smooth muscle cells. Circ. Res. 1994;75:1–7
  11. Koch AE, Polverini PJ, Kunkel SL, et al.  Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science. 1992;258:1798–1801
  12. Luster AD. Chemokines—chemotactic cytokines that mediate inflammation. N. Engl. J. Med. 1998;338:436–445
  13. Graves DT, Jiang Y. Chemokines, a family of chemotactic cytokines. Crit. Rev. Oral Biol. Med. 1995;6:109–118
  14. Onozaki K, Akiyama Y, Okano A, et al.  Synergistic regulatory effects of interleukin-6 and interleukin-1 on the growth and differentiation of human and mouse myeloid leukemic cell lines. Cancer Res. 1989;49:3602–3607
  15. Ikeda U, Ikeda M, Oohara T, et al.  Interleukin stimulates growth of vascular smooth muscle cells in a PDGF-dependent manner. Am. J. Physiol. 1991;260:H1713–H1717
  16. Loppnow H, Libby P. Proliferating or interleukin-1-activated human vascular smooth muscle cells secrete copious interleukin-6. J. Clin. Invest. 1990;85:731–738
  17. Wu D, Koga T, Martin KR, Meydani M. Effect of Vitamin E on human aortic endothelial cell production of chemokines and adhesion to monocytes. Atherosclerosis. 1999;147:297–307
  18. Martin KR, Wu D, Meydani M. The effect of carotenoids on the expression of cell surface adhesion molecules and binding of monocytes to human aortic endothelial cells. Atherosclerosis. 2000;150:265–274
  19. Devaraj S, Li D, Jialal I. The effects of alpha tocopherol supplementation on monocyte function. Decreased lipid oxidation, interleukin-1-beta secretion, and monocyte adhesion to endothelium. J. Clin. Invest. 1996;98:756–763
  20. Koga T, Meydani M. Effect of plasma metabolites of (+)-catechin and quercetin on monocyte adhesion to human aortic endothelial cells. Am. J. Clin. Nutr. 2001;73:941–948
  21. Anderson JW. Dietary fibre % complex carbohydrate and coronary artery disease. Can. J. Cardiol. 1995;11(Suppl G):55G–62G
  22. Katz DL, Nawaz H, Boukhalil J, et al.  Effects of oat and wheat cereals on endothelial responses. Prev. Med. 2001;33:476–484
  23. Collins FW. Oat phenolics: structure, occurence and function. In: Webster FH, editor. Oats: chemistry and technology. St. Paul, MN: American Association of Cereal Chemists; 1986. p. 227–95.
  24. Collins FW. Oatphenolics: avenanthramides, novel substituted N-cinnamoylanthranilate alkaloids from oat groats and hulls. J. Agric. Food Chem. 1989;37:60–66
  25. Collins FW, McLachlan DC, Blackwell BA. Oat phenolics: avenalumic acids, a new group of bound phenolics acids from oat groats and hulls. Cereal Chem. 1991;68:184–189
  26. Collins FW, Mullin WJ. High-performance liquid chromatographic determination of avenanthramides, N-aroylanthranilic acid alkaloids from oats. J. Chromatogr. 1988;45:363–370
  27. Dimberg LH, Theander O, Lingnert H. Avenanthramides—a group of phenolic antioxidants in oats. Cereal Chem. 1993;70:637–641
  28. Peterson DM, Hahn M, Emmons CL. Oat avenanthramides exhibit antioxidant activities in vitro. Food Chem. 2002;79:473–478
  29. Bratt K, Sunnerheim K, Bryngelsson S, et al.  Avenanthramides in oats (Avena sativa L.) and structure-antioxidant activity relationships. J. Agric. Food Chem. 2003;51:594–600
  30. Emmons CL, Peterson DM, Paul GL. Antioxidant capacity of oat (Avena sativa L.) extracts. 2. In vitro antioxidant activity and contents of phenolic and tocol antioxidants. J. Agric. Food Chem. 1999;47:4894–4898
  31. Peterson DM, Emmons CL, Hibbs AH. Phenolic antioxidants and antioxidant activity in pearling fractions of oat groats. J. Cereal Sci. 2001;33:97–103
  32. Emmons CL, Peterson DM. Antioxidant activity and phenolic content of oat as affected by cultivar and location. Crop Sci. 2001;41:1676–1681
  33. Krishnaswamy G, Kelley J, Yerra L, Smith JK, Chi DS. Human endothelium as a source of multifunctional cytokines: molecular regulation and possible role in human disease. J. Interferon Cytokine Res. 1999;19:91–104
  34. DiCorleto PE, de la Motte CA. Characterization of the adhesion of the human monocytic cell line U937 to cultured endothelial cells. J. Clin. Invest. 1985;75:1153–1161
  35. Vaporciyan AA, Jones ML, Ward PA. Rapid analysis of leukocyte–endothelial adhesion. J. Immunol. Methods. 1993;159:93–100
  36. Collins FW, Fielder DA, Starr AB, Redmond MJ, D’Attilio RZ, Process for the isolation, purification and recovery of non-polar extractives. US Patent #6, 495, 140, 2002.
  37. Meydani SN, Meydani M, Blumberg JB, et al.  Vitamin E supplementation and in vivo immune response in healthy elderly subjects: a randomized controlled trial. JAMA. 1997;277:1366–1380
  38. Yue TL, McKenna PJ, Gu JL, Feuerstein GZ. Interleukin-8 is chemotactic for vascular smooth muscle cells. Eur. J. Pharmacol. 1993;240:81–84
  39. Apostolopoulos J, Davenport P, Tipping PG. Interleukin-8 production by macrophages from atheromatousplaques. Arterioscler. Thromb. Vasc. Biol. 1996;16:1007–1012
  40. Nakae H, Endo S, Inada K, Kasai T, Yoshida M. Significance of alpha-tocopherol and interleukin-8 in septic adult respiratory distress syndrome. Res. Commun. Chem. Pathol. Pharmacol. 1994;84:197–202
  41. Simonini A, Moscucci M, Muller DW, et al.  IL-8 is an angiogenic factor in human coronary atherectomy tissue. Circulation. 2000;101:1519–1526
  42. Berkhout TA, Sarau HM, Moores K, et al.  Cloning, in vitro expression, and functional characterization of a novel human CC chemokine of the monocyte chemotactic protein (MCP) family (MCP-4) that binds and signals through the CC chemokine receptor 2B. J. Biol. Chem. 1997;272:16404–16413
  43. Cushing SD, Berliner JA, Valente AJ, et al.  Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc. Natl. Acad. Sci. U.S.A. 1990;87:5134–5138
  44. Wilcox JN, Nelken NA, Coughlin SR, Gordon D, Schall TJ. Local expression of inflammatory cytokines in human atherosclerotic plaques. J. Atheroscler. Thromb. 1994;1:S10–S13
  45. Nelken NA, Coughlin SR, Gordon D, Wilcox JN. Monocyte chemoattractantprotein-1 in human atheromatousplaques. J. Clin. Invest. 1991;88:1121–1127
  46. Yokota T, Hansson GK. Immunological mechanisms in atherosclerosis. J. Intern. Med. 1995;238:479–489
  47. Watson C, Whittaker S, Smith N, et al.  IL-6 acts on endothelial cells to preferentially increase their adherence for lymphocytes. Clin. Exp. Immunol. 1996;105:112–119
  48. Libby P, Hansson GK. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab. Invest. 1991;64:5–15
  49. Basha BJ, Sowers JR. Atherosclerosis: an update. Am. Heart J. 1996;131:1192–1202
  50. Krieglstein CF, Granger DN. Adhesion molecules and their role in vascular disease. Am. J. Hypertens. 2001;14:44S–54S
  51. Tedgui A, Bernard C. Cytokines, immuno-inflammatory response and atherosclerosis. Eur. Cytokine Netw. 1994;5:263–270
  52. Printseva O, Peclo MM, Gown AM. Various cell types in human atherosclerotic lesions express ICAM-1. Further immunocytochemical and immunochemical studies employing monoclonal antibody 10F3. Am. J. Pathol. 1992;140:889–896
  53. Poston RN, Haskard DO, Coucher JR, Gall NP, Johnson-Tidey RR. Expression of intercellular adhesion molecule-1 in atherosclerotic plaques. Am. J. Pathol. 1992;140:665–673
  54. Whelan J, Ghersa P, Hooft van Huijsduijnen R, et al.  An NF kappa B-like factor is essential but not sufficient for cytokine induction of endothelial leukocyte adhesion molecule 1 (ELAM-1) gene transcription. Nucl. Acids Res. 1991;19:2645–2653
  55. Collins T, Read MA, Neish AS, et al.  Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J. 1995;9:899–909
  56. Christman JW, Lancaster LH, Blackwell TS. Nuclear factor kappa B: a pivotal role in the systemic inflammatory response syndrome and new target for therapy. Intensive Care Med. 1998;24:1131–1138
  57. Schreck RK, Alberman K, Baeuerle PA. Nuclear factor κB: an oxidative stree-response transcription factor of eukaryotic cells. Free Radic. Res. Commun. 1992;17:221–237
  58. Van den Berg R, Haenen GR, van den Berg H, Bast A. Transcription factor NF-kappaB as a potential biomarker for oxidative stress. Br. J. Nutr. 2001;86(Suppl 1):S121–S127
  59. Mirochnitchenko O, Inouye M. Effect of overexpression of human Cu, Zn superoxide dismutase in transgenic mice on macrophage functions. J. Immunol. 1996;156:1578–1586
  60. Bell S, Goldman VM, Bistrian BR, et al.  Effect ofbeta-glucan from oats and yeast on serum lipids. Crit. Rev. Food Sci. Nutr. 1999;39:189–202
  61. Truswell AS. Dietary fibre and plasma lipids. Eur. J. Clin. Nutr. 1995;49(Suppl 3):S105–S109
  62. Tamai H, Katoh K, Yamaguchi T, et al.  The impact of tranilast on restenosis after coronary angioplasty: the Second Tranilast Restenosis Following Angioplasty Trial (TREAT-2). Am. Heart J. 2002;143:506–513
  63. Rosanio S, Tocchi M, Patterson C, Runge MS. Prevention of restenosis after percutaneous coronary interventions: the medical approach. Thromb. Haemost. 1999;82(Suppl 1):164–170
  64. Slobodzian DK, Hsieh JY, Bayne WF. Simultaneous determination of tranilast and metabolites in plasma and urine using high-performance liquid chromatography. J. Chromatogr. 1985;345:345–354
  65. Miyazawa K, Kikuchi S, Fukuyama J, Hamano S, Ujiie A. Inhibition of PDGF- and TGF-beta-1-induced collagen synthesis, migration and proliferation by tranilast in vascular smooth muscle cells from spontaneously hypertensive rats. Atherosclerosis. 1995;118:213–221
  66. Takahashi A, Taniguchi T, Ishikawa Y, Yokoyama M. Tranilast inhibits vascular smooth muscle cell growth and intimal hyperplasia by induction of p21(waf1/cip1/sdi1) and p53. Circ. Res. 1999;84:543–550
  67. Spiecker M, Lorenz I, Marx N, Darius H. Tranilast inhibits cytokine-induced nuclear factor kappaB activation in vascular endothelial cells. Mol. Pharmacol. 2002;62:856–863
  68. Chikaraishi A, Hirahashi J, Takase O, et al.  Tranilast inhibits interleukin-1-beta-induced monocyte chemoattractantprotein-1 expression in rat mesangial cells. Eur. J. Pharmacol. 2001;427:151–158

PII: S0021-9150(04)00149-2

doi: 10.1016/j.atherosclerosis.2004.01.044

Atherosclerosis
Volume 175, Issue 1 , Pages 39-49 , July 2004

Article Tools

* Image Usage & Resolution